No Data
No Data
Piper Sandler Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Cuts Target Price to $6
Fulcrum Therapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
A Quick Look at Today's Ratings for Fulcrum Therapeutics(FULC.US), With a Forecast Between $2 to $14
Fulcrum Therapeutics Analyst Ratings
Fulcrum Therapeutics Full Year 2024 Earnings: EPS Misses Expectations
Earnings Call Summary | Fulcrum Therapeutics(FULC.US) Q4 2024 Earnings Conference